Literature DB >> 18709302

Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study.

Olivier Dereure1, Nicolas Jumez, Didier Bessis, Benoit Gallix, Bernard Guillot.   

Abstract

Liver iron content was evaluated by a magnetic resonance imaging-based method in 20 consecutive patients with either sporadic or familial porphyria cutanea tarda. Serum ferritin, hepatitis C infection and the presence of the 2 main mutations of the hemochromatosis gene were also investigated. All patients showed good clinical response to phlebotomy. Initial liver iron content was normal (< 40 micromol/g) in 9 cases, slightly increased (40-59 micromol/g) in 3 cases, moderately increased (60-99 micromol/g) in 6 cases or markedly increased (100-199 micromol/g) in 2 cases). The ferritin level was raised (> 400 ng/ml) in 14/20 patients and there was no obvious relationship with liver iron. Increased liver iron content was observed more frequently in patients with hemochromatosis mutation and less frequent in those with hepatitis C infection. Clinical response to phlebotomies was slightly better in patients with increased liver iron content even slightly, but patients with normal liver iron content also responded well, which suggests that iron depletion is an outstanding treatment independent of liver iron content. This study shows that increased liver iron content is not a constant finding in patients with porphyria cutanea tarda, especially in women, and that it is not a prerequisite for the efficiency of phlebotomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18709302     DOI: 10.2340/00015555-0472

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  7 in total

Review 1.  Liver iron content determination by magnetic resonance imaging.

Authors:  Konstantinos Tziomalos; Vassilios Perifanis
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 2.  Hepatitis C, porphyria cutanea tarda and liver iron: an update.

Authors:  F Ryan Caballes; Hossein Sendi; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2012-04-17       Impact factor: 5.828

3.  Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis.

Authors:  H Salameh; H Sarairah; M Rizwan; Y-F Kuo; K E Anderson; A K Singal
Journal:  Br J Dermatol       Date:  2018-07-26       Impact factor: 9.302

4.  Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda.

Authors:  Ashwani K Singal; Csilla Kormos-Hallberg; Chul Lee; Vaithamanithi M Sadagoparamanujam; James J Grady; Daniel H Freeman; Karl E Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-14       Impact factor: 11.382

Review 5.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

Review 6.  Nutrients and Porphyria: An Intriguing Crosstalk.

Authors:  Elena Di Pierro; Francesca Granata
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

7.  Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy.

Authors:  Akihiro Yoshida; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Ida; Toshiharu Sakurai; Yoriaki Komeda; Kentaro Yamao; Mamoru Takenaka; Eisuke Enoki; Masatomo Kimura; Masako Miyake; Akira Kawada; Masatoshi Kudo
Journal:  Intern Med       Date:  2018-09-01       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.